Papers
2
Total Citations
113
H-Index
2
About
Dr. Apar Pataer is a leading surgical oncologist whose research focuses on optimizing neoadjuvant immunotherapy strategies for non–small cell lung cancer (NSCLC). Her major contributions center on evaluating the safety and efficacy of combining immune checkpoint inhibitors—specifically nivolumab and ipilimumab—with chemotherapy prior to surgical resection. In her landmark 2022 study, cited 94 times, she demonstrated that neoadjuvant nivolumab alone or with ipilimumab yields favorable surgical outcomes, including high rates of pathological response and manageable perioperative morbidity. Building on this, her 2023 work (19 citations) compared chemotherapy plus nivolumab versus chemotherapy plus both nivolumab and ipilimumab, providing critical insights into the optimal sequencing and combination of immunotherapies. Dr. Pataer’s research has directly influenced clinical guidelines for resectable NSCLC, offering evidence that immunotherapy can be safely integrated into preoperative regimens without compromising surgical feasibility. Her work bridges the gap between medical oncology and thoracic surgery, advancing personalized treatment paradigms that improve survival and quality of life for lung cancer patients. Through these high-impact studies, she has established herself as a key voice in the evolving field of neoadjuvant immunotherapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2